Pharmacogenetics of warfarin: clinical implications

Warfarin pharmacogenetics meets clinical use.

ence is sufficient to disrupt the nucleolar structure.9 Similarly, the anticancer peptide CIGB-300 leads to nucleolar disassembly and apoptosis, most likely through its capability to bind NPM1.10 Because AML cells carrying the NPM1 mutation are depleted of wild-type NPM1 protein in their nucleolar pool (because of haploinsufficiency and cytoplasmic dislocation through formation of heterodimers ...

Warfarin Pharmacogenetics: A Rising Tide for its Clinical Value Running title: Johnson, Clinical utility of warfarin pharmacogenetics

Pharmacogenetics of Warfarin

วารสารโลหติวทิยาและเวชศาสตร บรกิารโลหติ ป ที ่ 16 ฉบบัที ่ 3 กรกฎาคม-กนัยายน 2549 Warfarin is the mainstay of anticoagulation therapy. It is used for the prevention and treatment of venous thromboembolism, myocardial infarction, and strokes.1 Its clinical use, however, is complicated by the fact that it has a narrow therapeutic index with associated adverse effects that are potentially serious,...

Clinical implications of opioid pharmacogenetics.

The peer-reviewed literature yields a plethora of examples of variability in patient's responses to medications. The rapidly progressing field of pharmacogenetics offers insight into the variation in responses observed clinically, and in particular for the variability observed among patients administered mu opioid analgesics. Genetic variation leads to interperson variability in drug absorption...

Warfarin pharmacogenetics: a rising tide for its clinical value.